CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

CRISPR-phage antibacterials to address the antibiotic resistance crisis : scientific, economic, and regulatory considerations. / Pacia, Danielle M.; Brown, Beatrice L.; Minssen, Timo; Darrow, Jonathan J.

In: Journal of Law and the Biosciences, Vol. 11, No. 1, lsad030, 01.01.2024.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pacia, DM, Brown, BL, Minssen, T & Darrow, JJ 2024, 'CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations', Journal of Law and the Biosciences, vol. 11, no. 1, lsad030. https://doi.org/10.1093/jlb/lsad030

APA

Pacia, D. M., Brown, B. L., Minssen, T., & Darrow, J. J. (2024). CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations. Journal of Law and the Biosciences, 11(1), [lsad030]. https://doi.org/10.1093/jlb/lsad030

Vancouver

Pacia DM, Brown BL, Minssen T, Darrow JJ. CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations. Journal of Law and the Biosciences. 2024 Jan 1;11(1). lsad030. https://doi.org/10.1093/jlb/lsad030

Author

Pacia, Danielle M. ; Brown, Beatrice L. ; Minssen, Timo ; Darrow, Jonathan J. / CRISPR-phage antibacterials to address the antibiotic resistance crisis : scientific, economic, and regulatory considerations. In: Journal of Law and the Biosciences. 2024 ; Vol. 11, No. 1.

Bibtex

@article{bbb76b6e96464a9a9e3b54b9f8ddefe9,
title = "CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations",
abstract = "Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability",
keywords = "antibacterials, CRISPR, CRISPR-phage, individualized therapies, new genomic technologies, phage therapies, public health",
author = "Pacia, {Danielle M.} and Brown, {Beatrice L.} and Timo Minssen and Darrow, {Jonathan J.}",
note = "Funding Information: Timo Minssen{\textquoteright}s and Jonathan J. Darrow{\textquoteright}s research for this paper was supported by a Novo Nordisk Foundation Grant for a scientifically independent International Collaborative Bioscience Innovation & Law Programme (Inter-CeBIL programme - grant no. NNF23SA0087056). Jonathan J. Darrow also received funding from Arnold Ventures.",
year = "2024",
month = jan,
day = "1",
doi = "10.1093/jlb/lsad030",
language = "English",
volume = "11",
journal = "Journal of Law and the Biosciences",
issn = "2053-9711",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - CRISPR-phage antibacterials to address the antibiotic resistance crisis

T2 - scientific, economic, and regulatory considerations

AU - Pacia, Danielle M.

AU - Brown, Beatrice L.

AU - Minssen, Timo

AU - Darrow, Jonathan J.

N1 - Funding Information: Timo Minssen’s and Jonathan J. Darrow’s research for this paper was supported by a Novo Nordisk Foundation Grant for a scientifically independent International Collaborative Bioscience Innovation & Law Programme (Inter-CeBIL programme - grant no. NNF23SA0087056). Jonathan J. Darrow also received funding from Arnold Ventures.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability

AB - Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability

KW - antibacterials

KW - CRISPR

KW - CRISPR-phage

KW - individualized therapies

KW - new genomic technologies

KW - phage therapies

KW - public health

UR - http://www.scopus.com/inward/record.url?scp=85183863386&partnerID=8YFLogxK

U2 - 10.1093/jlb/lsad030

DO - 10.1093/jlb/lsad030

M3 - Journal article

C2 - 38283616

AN - SCOPUS:85183863386

VL - 11

JO - Journal of Law and the Biosciences

JF - Journal of Law and the Biosciences

SN - 2053-9711

IS - 1

M1 - lsad030

ER -

ID: 386669784